MedKoo Cat#: 319670 | Name: Doravirine
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doravirine, also known as MK-1439, is a non-nucleoside reverse transcriptase inhibitor under development by Merck & Co. for use in the treatment of HIV/AIDS. MK-1439 is a novel NNRTI with a 50% inhibitory concentration (IC50) of 12, 9.7, and 9.7 nM against the wild type (WT) and K103N and Y181C reverse transcriptase (RT) mutants, respectively. MK-1439 showed excellent potency in suppressing the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC95 of 43, 27, and 55 nM, respectively. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).

Chemical Structure

Doravirine
Doravirine
CAS#1338225-97-0

Theoretical Analysis

MedKoo Cat#: 319670

Name: Doravirine

CAS#: 1338225-97-0

Chemical Formula: C17H11ClF3N5O3

Exact Mass: 425.0503

Molecular Weight: 425.75

Elemental Analysis: C, 47.96; H, 2.60; Cl, 8.33; F, 13.39; N, 16.45; O, 11.27

Price and Availability

Size Price Availability Quantity
5mg USD 110.00 Ready to ship
10mg USD 190.00 Ready to ship
25mg USD 350.00 Ready to ship
50mg USD 650.00 Ready to ship
100mg USD 950.00 Ready to ship
200mg USD 1,750.00 Ready to ship
500mg USD 2,450.00 Ready to ship
1g USD 3,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MK 1439; MK-1439; MK1439; Doravirine; Pifeltro.
IUPAC/Chemical Name
3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile
InChi Key
ZIAOVIPSKUPPQW-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
SMILES Code
N#CC1=CC(OC2=C(C(F)(F)F)C=CN(CC(N3C)=NNC3=O)C2=O)=CC(Cl)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMSO 92.5 217.26
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 425.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Spinner CD, Barber TJ. Are 96-week data enough for doravirine to DRIVE FORWARD? Lancet HIV. 2019 Nov 15. pii: S2352-3018(19)30370-4. doi: 10.1016/S2352-3018(19)30370-4. [Epub ahead of print] PubMed PMID: 31740350. 2: Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2019 Nov 15. pii: S2352-3018(19)30336-4. doi: 10.1016/S2352-3018(19)30336-4. [Epub ahead of print] PubMed PMID: 31740348. 3: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548267/ PubMed PMID: 31643591. 4: Hwang C, Lai MT, Hazuda DJ. Rational Design of Doravirine: From Bench to Patients. ACS Infect Dis. 2019 Oct 17. doi: 10.1021/acsinfecdis.9b00178. [Epub ahead of print] PubMed PMID: 31621289. 5: Greaves W, Wan H, Yee KL, Kandala B, Vaddady P, Hwang C. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.01298-19. doi: 10.1128/AAC.01298-19. [Epub ahead of print] PubMed PMID: 31548188; PubMed Central PMCID: PMC6879224. 6: Desai R, Roadcap B, Goykhman D, Woolf E. Determination of doravirine in human plasma using liquid-liquid extraction and HPLC-MS/MS. Bioanalysis. 2019 Aug;11(16):1495-1508. doi: 10.4155/bio-2019-0116. Epub 2019 Sep 10. PubMed PMID: 31502859. 7: Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration. Antivir Ther. 2019 Aug 21. doi: 10.3851/IMP3324. [Epub ahead of print] PubMed PMID: 31433304. 8: Wong A, Goldstein D, Mallolas J, DeJesus E, Johnson M, Molina JM, Pozniak A, Rodgers A, Teal V, Hepler D, Kumar S, Sklar P, Hanna GJ, Hwang C, Badshah C, Teppler H. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153. PubMed PMID: 31425317; PubMed Central PMCID: PMC6830961. 9: Blevins SR, Hester EK, Chastain DB, Cluck DB. Doravirine: A Return of the NNRTI Class? Ann Pharmacother. 2020 Jan;54(1):64-74. doi: 10.1177/1060028019869641. Epub 2019 Aug 15. PubMed PMID: 31416335. 10: Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo): Merck Canada Inc. Indication: A complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK544820/ PubMed PMID: 31393687. 11: Pharmacoeconomic Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK544856/ PubMed PMID: 31393683. 12: Clinical Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK544868/ PubMed PMID: 31393682. 13: Boyle A, Moss CE, Marzolini C, Khoo S. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clin Pharmacokinet. 2019 Dec;58(12):1553-1565. doi: 10.1007/s40262-019-00806-9. Review. PubMed PMID: 31388941. 14: Patient Input: doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo): (Merck Canada Inc.): Indication: HIV Infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Nov 5. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK544593/ PubMed PMID: 31369220. 15: CADTH Canadian Drug Expert Committee Recommendation: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo — Merck Canada Inc.): Indication: As a complete regimen for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to doravirine (DOR), lamivudine (3TC), or tenofovir [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 16. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK544511/ PubMed PMID: 31356038. 16: CADTH Canadian Drug Expert Committee Recommendation: Doravirine (Pifeltro — Merck Canada Inc.): Indication: In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine (DOR) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 16. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK544510/ PubMed PMID: 31356037. 17: Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antivir Ther. 2019 Jul 29. doi: 10.3851/IMP3323. [Epub ahead of print] PubMed PMID: 31355775. 18: Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis. 2019 May 23. pii: ciz424. doi: 10.1093/cid/ciz424. [Epub ahead of print] PubMed PMID: 31121015. 19: Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis. Clin Infect Dis. 2019 May 23. pii: ciz423. doi: 10.1093/cid/ciz423. [Epub ahead of print] PubMed PMID: 31121013. 20: Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Fan L, Searle S, Bouhajib M, Iwamoto M. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone. Clin Pharmacol Drug Dev. 2019 May 23. doi: 10.1002/cpdd.699. [Epub ahead of print] PubMed PMID: 31120195.